The potential palliative role and possible immune modulatory effects of low-dose total body irradiation in relapsed or chemo-resistant non-Hodgkin's lymphoma

Radiotherapy and Oncology

Volumn 69, Issue 1, 2003, Pages 33-36

  Safwat, Akmal ^a,b   Bayoumy, Yasser ^a   El Sharkawy, Nahla ^a   Shaaban, Khaled ^a   Mansour, Osman ^a   Kamel, Azza ^a  

^a NATIONAL CANCER INSTITUTE   (Egypt)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Low dose total body irradiation; Non Hodgkin's lymphoma; Relapse; Toxicity; Treatment results

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RECURRENT CANCER; SURVIVAL TIME; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0242384205     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(03)00247-0     Document Type: Article

References (15)

1. Brandt L., Kimby E., Nygren P., Glimelius B. A systemic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol. 40:2001;213-223.
2. Clave E., Socie G., Cosset J.M., et al. Multicolor flow cytometry analysis of blood cell subsets in patients given total body irradiation before bone marrow transplantation. Int J Radiat Oncol Biol Phys. 33:1995;881-886.
3. Fourquet A., Teillaud J.L., Lando D., Fridman W.H. Effects of low dose total body irradiation and recombinant human interlukin-2 in mice. Radiother Oncol. 26:1993;219-225.
4. Gohring B., Riemann D., Rebmann U., Heynemann H., Schabel J., Langner J. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/INF-alpha-2 in combination with 5-FU. Urol Res. 24:1996;297-303.
5. Hashimoto S., Shirato H., Hosokawa M., et al. The suppression of metastases and the change in host immune response after low-dose total body irradiation in tumor bearing rats. Radiat Res. 151:1999;717-724.
6. Hoppe R.T., Kushlan P., Kaplan H.S. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomised trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood. 58:1981;592-598.
7. Keller R.H., Calvanico N.J., Stevens H.O. Hypersensitivity pneumonitis in nonhuman primates: I. Studies on the relationship of immunoregulation and disease activity. J Immunol. 128:1982;116-128.
8. Kimby E., Brandt L., Nygren P., Glimelius B. A systemic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol. 40:2001;198-212.
9. Pettingale K.W. The management of grade 2 non-Hodgkin's lymphomas: British national lymphoma investigation report no 18. Clin Radiol. 7:1981;553-556.
10. Quast U. Physical treatment planning of total body irradiation: patient translation and beam zone method. Med Phys. 12:1985;567-573.
11. Richaud P.M., Soubeyran P., Eghbali H., et al. Place of low-dose total body irradiation in the treatment of localized follicular NHL: results of a pilot study. Int J Radiat Oncol Biol Phys. 40:1998;387-390.
12. Safwat A. The role of low-dose total body irradiation in treatment of NHL: a new look at an old method. Radiother Oncol. 56:2000;1-8.
13. Takai Y., Ogawa Y., Yamada S., Sakamoto K. Two-color analysis of peripheral blood lymphocytes in patients with malignant tumours after low dose half or total body irradiation: a pilot study. Nippon Gam Chiryo Gakkai Shi. 24:1989;1288-1295.
14. WHO handbook for reporting results of cancer treatment. 2001. Geneva: WHO off set publication; 1979.
15. Yonkosky D.M., Feldman M.I., Cathcart E.S., Kim S. Improvement of in-vitro mitogen proliferative reponses in non-Hodgkin's lymphoma patients exposed to fractionated total body irradiation. Cancer. 42:1978;1204-1210.